North America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User
The anticoagulant reversal drug market in North America is expected to grow from US$ 414. 7 million in 2019 to US$ 1,037. 9 million by 2027; it is estimated to grow at a CAGR of 12. 8% from 2019 to 2027.
May 27, 2021 05:30 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, May 27, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report North America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User - https://www.reportlinker.com/p06075726/?utm source=GNW Anticoagulant reversal drugs are used in the management of hemorrhagic stroke to lower bleeding and allow tissues to recover. As per the CDC, in 2018, 1 in every 6 deaths in the US from cardiovascular disease was due to stroke. It also mentioned that 1
South and Central America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User
The anticoagulant reversal drug market in South and Central America is expected to grow from US$ 29. 8 million in 2019 to US$ 63. 1 million by 2027; it is estimated to grow at a CAGR of 10. 5% from 2019 to 2027.
May 25, 2021 06:03 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, May 25, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report South and Central America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User - https://www.reportlinker.com/p06075778/?utm source=GNW
Esperion Therapeutics (ESPR) Appoints Sheldon Koenig as President and CEO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ESPERION Appoints Sheldon Koenig as President and CEO
May 17, 2021 09:01 ET | Source: Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. Ann Arbor, Michigan, UNITED STATES Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space;
previously served as ESPERION COO Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor –
ANN ARBOR, Mich., May 17, 2021 (GLOBE NEWSWIRE) ESPERION (NASDAQ: ESPR), today announced the appointment of Sheldon Koenig as president and chief executive officer and board member, effective immediately. With over 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space, Mr. Koenig has served as the company’s chief operating officer since December 2020. He is succeeding Tim Mayleben, who after serving in this role for